{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:56:52Z","timestamp":1791266212527,"version":"4.1.0"},"reference-count":54,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2013,8,21]],"date-time":"2013-08-21T00:00:00Z","timestamp":1377043200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0072030","type":"journal-article","created":{"date-parts":[[2013,8,21]],"date-time":"2013-08-21T21:03:12Z","timestamp":1377118992000},"page":"e72030","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":36,"title":["Hyaluronan and N-ERC\/Mesothelin as Key Biomarkers in a Specific Two-Step Model to Predict Pleural Malignant Mesothelioma"],"prefix":"10.1371","volume":"8","author":[{"given":"Filip","family":"Mundt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustav","family":"Nilsonne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serta\u00e7","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karola","family":"Cs\u00fcr\u00f6s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Hillerdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huseyin","family":"Yildirim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzaffer","family":"Metintas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Dobra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Hjerpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,8,21]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1440-1843.2005.00714.x","article-title":"Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma","volume":"10","author":"DH Sterman","year":"2005","journal-title":"Respirology"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/dc.20202","article-title":"The combination of CEA, EMA, and BerEp4 and hyaluronan analysis specifically identifies 79% of all histologically verified mesotheliomas causing an effusion","volume":"32","author":"A Dejmek","year":"2005","journal-title":"Diagn Cytopathol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.lungcan.2009.05.004","article-title":"Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions","volume":"68","author":"C Flores-Staino","year":"2010","journal-title":"Lung Cancer"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/PAT.0b013e32835bc848","article-title":"A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit","volume":"45","author":"A Segal","year":"2013","journal-title":"Pathology"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1158\/1055-9965.EPI-05-0334","article-title":"Mesothelin variant 1 is released from tumor cells as a diagnostic marker","volume":"15","author":"I Hellstrom","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1349-7006.2006.00246.x","article-title":"Novel ELISA system for detection of N-ERC\/mesothelin in the sera of mesothelioma patients","volume":"97","author":"K Shiomi","year":"2006","journal-title":"Cancer Sci"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1164\/rccm.200511-1789OC","article-title":"Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma","volume":"173","author":"A Scherpereel","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S0140-6736(03)14794-0","article-title":"Mesothelin-family proteins and diagnosis of mesothelioma","volume":"362","author":"BW Robinson","year":"2003","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.clinbiochem.2009.03.007","article-title":"Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma","volume":"42","author":"B Grigoriu","year":"2009","journal-title":"Clin Biochem"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.lungcan.2011.02.007","article-title":"Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma\u2013which is best?","volume":"74","author":"J Creaney","year":"2011","journal-title":"Lung Cancer"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/clinchem\/40.5.777","article-title":"Clinical utility of liquid-chromatographic analysis of effusions for hyaluronate content","volume":"40","author":"M Nurminen","year":"1994","journal-title":"Clin Chem"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1002\/1097-0142(19870615)59:12<2104::AID-CNCR2820591224>3.0.CO;2-I","article-title":"Serum hyaluronate in malignant pleural mesothelioma","volume":"59","author":"T Frebourg","year":"1987","journal-title":"Cancer"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1378\/chest.94.5.1037","article-title":"Concentration of hyaluronic acid in pleural fluid as a diagnostic aid for malignant mesothelioma","volume":"94","author":"T Pettersson","year":"1988","journal-title":"Chest"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/1097-0142(20010901)92:5<1224::AID-CNCR1441>3.0.CO;2-U","article-title":"Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma","volume":"92","author":"A Thylen","year":"2001","journal-title":"Cancer"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1056\/NEJMoa051185","article-title":"Asbestos exposure, pleural mesothelioma, and serum osteopontin levels","volume":"353","author":"HI Pass","year":"2005","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1158\/1078-0432.CCR-06-2144","article-title":"Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment","volume":"13","author":"BD Grigoriu","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1309\/TWCQV536WWRNEU51","article-title":"Prognostic role of osteopontin expression in malignant pleural mesothelioma","volume":"130","author":"S Cappia","year":"2008","journal-title":"Am J Clin Pathol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/JTO.0b013e318180477b","article-title":"Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma","volume":"3","author":"J Creaney","year":"2008","journal-title":"J Thorac Oncol"},{"key":"ref19","first-page":"4060","article-title":"Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer","volume":"7","author":"NS Fedarko","year":"2001","journal-title":"Clin Cancer Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1432-0436.2000.660404.x","article-title":"Upregulation of 9 genes, including that for thioredoxin, during epithelial differentiation of mesothelioma cells","volume":"66","author":"X Sun","year":"2000","journal-title":"Differentiation"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0215(20010520)95:3<198::AID-IJC1034>3.0.CO;2-F","article-title":"Up-regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma","volume":"95","author":"K Kahlos","year":"2001","journal-title":"Int J Cancer"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0014-5793(00)01913-X","article-title":"Differential gene expression in mesothelioma","volume":"480","author":"BH Rihn","year":"2000","journal-title":"FEBS Lett"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.biochi.2003.11.008","article-title":"Microdissection, mRNA amplification and microarray: a study of pleural mesothelial and malignant mesothelioma cells","volume":"86","author":"S Mohr","year":"2004","journal-title":"Biochimie"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/path.1312","article-title":"Proteoglycans and WT1 as markers for distinguishing adenocarcinoma, epithelioid mesothelioma, and benign mesothelium","volume":"199","author":"M Gulyas","year":"2003","journal-title":"J Pathol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/dc.20297","article-title":"Utility of CD138 (syndecan-1) in distinguishing carcinomas from mesotheliomas","volume":"33","author":"A Saqi","year":"2005","journal-title":"Diagn Cytopathol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1183\/09031936.00063109","article-title":"Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma","volume":"35","author":"A Scherpereel","year":"2010","journal-title":"Eur Respir J"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0731-7085(03)00569-7","article-title":"A sandwich ELISA for the estimation of human syndecan-2 and syndecan-4 in biological samples","volume":"34","author":"C Seidel","year":"2004","journal-title":"J Pharm Biomed Anal"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1083\/jcb.118.4.961","article-title":"Molecular cloning of amphiglycan, a novel integral membrane heparan sulfate proteoglycan expressed by epithelial and fibroblastic cells","volume":"118","author":"G David","year":"1992","journal-title":"J Cell Biol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/clinchem\/32.6.952","article-title":"Liquid-chromatographic determination of hyaluronic acid in pleural and ascitic fluids","volume":"32","author":"A Hjerpe","year":"1986","journal-title":"Clin Chem"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/sim.4780050506","article-title":"Probabilistic prediction in patient management and clinical trials","volume":"5","author":"DJ Spiegelhalter","year":"1986","journal-title":"Stat Med"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Pencina MJ, D\u2019Agostino RB Sr, D\u2019Agostino RB Jr, Vasan RS (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27: 157\u2013172; discussion 207\u2013112.","DOI":"10.1002\/sim.3106"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/EDE.0b013e3181c30fb2","article-title":"Assessing the performance of prediction models: a framework for traditional and novel measures","volume":"21","author":"EW Steyerberg","year":"2010","journal-title":"Epidemiology"},{"key":"ref33","unstructured":"Team RDC (2011) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria ISBN 3-900051-07-0."},{"key":"ref34","unstructured":"Rizopoulos D. bootStepAIC: Bootstrap stepAIC. R package version 1.2-0."},{"key":"ref35","unstructured":"Monica L-R, Maria XR-A (2012) OptimalCutpoints: Computing optimal cutpoints in diagnostic tests. R package version 1.0."},{"key":"ref36","unstructured":"Harrell FE. rms: Regression Modeling Strategies. R package version 3.4-0."},{"key":"ref37","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00428-007-0375-x","article-title":"Cytological diagnosis of malignant mesothelioma\u2013improvement by additional analysis of hyaluronic acid in pleural effusions","volume":"450","author":"L Welker","year":"2007","journal-title":"Virchows Arch"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/1097-0142(19940301)73:5<1406::AID-CNCR2820730515>3.0.CO;2-I","article-title":"The sensitivity of hyaluronan analysis of pleural fluid from patients with malignant mesothelioma and a comparison of different methods","volume":"73","author":"G Martensson","year":"1994","journal-title":"Cancer"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Yamada S, Tabata C, Tabata R, Fukuoka K, Nakano T (2011) Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma. Clin Chem Lab Med.","DOI":"10.1515\/CCLM.2011.242"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1164\/rccm.200811-1729OC","article-title":"Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions","volume":"180","author":"HE Davies","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.medcli.2008.11.047","article-title":"Pleural fluid mesothelin for the differential diagnosis of exudative pleural effusions","volume":"133","author":"C Aleman","year":"2009","journal-title":"Med Clin (Barc)"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, <etal>et al<\/etal>.. (2008) Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 85: 265\u2013272; discussion 272.","DOI":"10.1016\/j.athoracsur.2007.07.042"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/thx.2006.068114","article-title":"Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma","volume":"62","author":"J Creaney","year":"2007","journal-title":"Thorax"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/j.1440-1843.2009.01536.x","article-title":"Osteopontin is upregulated in malignant and inflammatory pleural effusions","volume":"14","author":"C Moschos","year":"2009","journal-title":"Respirology"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.lungcan.2008.02.012","article-title":"Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin","volume":"62","author":"K Iwahori","year":"2008","journal-title":"Lung Cancer"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1164\/rccm.200907-1020OC","article-title":"Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma","volume":"181","author":"K Hollevoet","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1183\/09031936.00226111","article-title":"Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma","volume":"41","author":"I Pantazopoulos","year":"2013","journal-title":"Eur Respir J"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1097\/JTO.0b013e3182272294","article-title":"Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma","volume":"6","author":"K Hollevoet","year":"2011","journal-title":"J Thorac Oncol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/PAT.0b013e3283445e67","article-title":"Molecular biomarkers in malignant mesothelioma: state of the art","volume":"43","author":"SC Kao","year":"2011","journal-title":"Pathology"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.bbrc.2009.03.042","article-title":"Tumorigenic properties of alternative osteopontin isoforms in mesothelioma","volume":"382","author":"SV Ivanov","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/1471-2407-6-207","article-title":"Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system","volume":"6","author":"D Vordermark","year":"2006","journal-title":"BMC Cancer"},{"key":"ref52","unstructured":"Tabata C, Tabata R, Nakano T (2011) Is serum thioredoxin-1 a useful clinical marker for malignant pleural mesothelioma? Antioxid Redox Signal."},{"key":"ref53","doi-asserted-by":"crossref","first-page":"e46091","DOI":"10.1371\/journal.pone.0046091","article-title":"Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool","volume":"7","author":"RM Ostroff","year":"2012","journal-title":"PLoS One"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/19338240903390305","article-title":"Endemic malignant mesothelioma: exposure to erionite is more important than genetic factors","volume":"65","author":"M Metintas","year":"2010","journal-title":"Arch Environ Occup Health"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0072030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,2]],"date-time":"2020-08-02T09:35:44Z","timestamp":1596360944000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0072030"}},"subtitle":[],"editor":[{"given":"Konradin","family":"Metze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,8,21]]},"references-count":54,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2013,8,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0072030","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,21]]}}}